Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.

Tytuł :
Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.
Autorzy :
Albay CEQ; Cardinal Santos Medical Center, 10 Wilson St. Greenhills West, 1502, San Juan City, NCR, Philippines. .
Leyson FGD; Cardinal Santos Medical Center, 10 Wilson St. Greenhills West, 1502, San Juan City, NCR, Philippines.
Cheng FC; Cardinal Santos Medical Center, 10 Wilson St. Greenhills West, 1502, San Juan City, NCR, Philippines.
Pokaż więcej
Źródło :
BMC neurology [BMC Neurol] 2020 Jun 03; Vol. 20 (1), pp. 224. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji :
Comparative Study; Journal Article; Meta-Analysis; Review; Retracted Publication
Język :
English
Imprint Name(s) :
Original Publication: London : BioMed Central, [2001-
MeSH Terms :
Ischemic Attack, Transient/*drug therapy
Platelet Aggregation Inhibitors/*administration & dosage
Stroke/*drug therapy
Aspirin/therapeutic use ; Brain Ischemia/drug therapy ; Drug Therapy, Combination ; Hemorrhage/chemically induced ; Humans ; Ischemic Attack, Transient/epidemiology ; Platelet Aggregation Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Stroke/epidemiology
References :
N Engl J Med. 2013 Jul 4;369(1):11-9. (PMID: 23803136)
Int J Stroke. 2013 Aug;8(6):479-83. (PMID: 23879752)
N Engl J Med. 2006 Apr 20;354(16):1706-17. (PMID: 16531616)
N Engl J Med. 2018 Jul 19;379(3):215-225. (PMID: 29766750)
Lancet. 2006 May 20;367(9523):1665-73. (PMID: 16714187)
Circulation. 2013 Oct 8;128(15):1656-66. (PMID: 24030500)
Lancet Neurol. 2010 Feb;9(2):159-66. (PMID: 20060783)
J Am Heart Assoc. 2019 Aug 6;8(15):e012652. (PMID: 31347430)
Stroke. 2010 Apr;41(4):732-8. (PMID: 20181679)
J Neurol Sci. 2012 Feb 15;313(1-2):22-6. (PMID: 22014645)
J Neurol Sci. 1996 Nov;143(1-2):1-13. (PMID: 8981292)
Chest. 2012 Feb;141(2 Suppl):e89S-e119S. (PMID: 22315278)
Stroke. 2016 Sep;47(9):2323-30. (PMID: 27418597)
Lancet Neurol. 2010 May;9(5):489-97. (PMID: 20335070)
Am Heart J. 2010 Sep;160(3):380-386.e1. (PMID: 20826243)
Circulation. 2005 May 3;111(17):2233-40. (PMID: 15851601)
Lancet Neurol. 2007 Nov;6(11):961-9. (PMID: 17931979)
Stroke. 1993 Jan;24(1):35-41. (PMID: 7678184)
Lancet. 2004 Jul 24-30;364(9431):331-7. (PMID: 15276392)
BMJ. 2018 Dec 18;363:k5108. (PMID: 30563866)
N Engl J Med. 2016 Jul 7;375(1):35-43. (PMID: 27160892)
Lancet Neurol. 2019 Jun;18(6):539-548. (PMID: 31122494)
Expert Opin Investig Drugs. 2007 Feb;16(2):225-9. (PMID: 17243942)
Contributed Indexing :
Keywords: Acute ischemic stroke; Aspirin; Cilostazol; Clopidogrel; Dipyridamole; Dual antiplatelet; Mono antiplatelet treatment; Non-cardioembolic stroke; Ticagrelor
Substance Nomenclature :
0 (Platelet Aggregation Inhibitors)
R16CO5Y76E (Aspirin)
Entry Date(s) :
Date Created: 20200605 Date Completed: 20200922 Latest Revision: 20210110
Update Code :
20211106
PubMed Central ID :
PMC7268473
DOI :
10.1186/s12883-020-01808-y
PMID :
32493229
Czasopismo naukowe
Background: New evidence on the efficacy and safety of dual antiplatelet therapy for secondary stroke prevention have been realized in the recent years. An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding.
Methods: PubMed, Cochrane and Science Direct data bases were utilized, RCTs evaluating dual antiplatelet vs mono antiplatelet therapy for acute ischemic stroke or transient ischemic attack within < 72 h from ictus were searched up to July 2019. Risk ratio at 95% confidence intervals were calculated to evaluate stroke recurrence, cardiac events and mortality, and major bleeding.
Results: Sixteen randomized controlled trials with a population of 28, 032 patients were pooled into a meta-analysis. Dual antiplatelet therapy was significantly superior over mono antiplatelet therapy in the reduction of stroke (RR 0.75, 95% CI:0.68-0.83, p value< 0.00001) and composite events namely cardiovascular morbidity and mortality (0.73 95% CI: 0.65-0.82, p value < 0.00001), while bleeding events were noted to be not significant (1.22 95% CI: 0.87-1.70, p value = 0.25).
Conclusion: In acute non-cardioembolic ischemic strokes or those who have suffered a transient ischemic attack, dual antiplatelet therapy was associated with efficacy in stroke recurrence and composite cardiac events, with a non-significant risk of major bleeding.
Retraction in: BMC Neurol. 2020 Dec 17;20(1):447. (PMID: 33334309)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies